4204-78-8

Usage

Uses

Used in Pharmaceutical Industry:
p-(2,3-Epoxypropoxy)benzyl Alcohol is used as an intermediate in the synthesis of Bisoprolol (B510500) derivatives for the development of cardiovascular medications. Its unique structure allows for the creation of compounds with potential therapeutic benefits in treating heart-related conditions.

Upstream product

• 623-05-2 (4-hydroxyphenyl)methanol 
• 3132-64-7 1,2-Epoxy-3-bromopropane 
• 106-89-8 epichlorohydrin 

Downstream Products

• 1029559-09-8 4-(2-hydroxy-3-methoxypropoxy)benzaldehyde 
• 1029559-43-0 1-(4-formylphenyl)-3-methoxypropane-2-one 
• 124933-24-0 1-(4-hydroxyphenoxy)-3-methoxypropan-2-ol 
• 1029559-07-6 1-[4-(hydroxymethyl)phenoxy]-3-methoxypropan-2-ol 
• 103576-84-7 rac‐(4‐((2,2‐dimethyl‐1,3‐dioxolan‐4‐yl)methoxy)phenyl)methanol 
• 1041190-95-7 1-(4-(hydroxymethyl)phenoxy)-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propan-2-ol 

Relevant academic research and scientific papers

Solid-phase synthesis of 1,3-oxazolidine derivatives

1,3-Oxazolidines 9 were synthesized by using a solid support. Regioselective ring opening of resin-bound epoxy ether 3 with ammonium chloride followed by nucleophilic substitution with sodium azide gave azido alcohol 7. Reduction of 7 provided 1-amino-2-alkanol 6, which was treated with various aldehydes and acyl chlorides or isocyanates to afford the corresponding 1,3-oxazolidines immobilized on Wang resin. Oxidative cleavage with DDQ from the solid support yielded 1,3-oxazolidines as a mixture of 10 (cis) and 11 (trans). (C) 2000 Elsevier Science Ltd.

EPOXY-(METH)ACRYLATE MONOMERS AND POLYMERS AND METHODS OF MAKING AND USING THE SAME

The present invention relates to the unexpected discovery of novel monomer compounds capable of crosslinking interpenetrating polymer networks (IPNs). In certain embodiments, the monomer compounds of the invention each comprise at least one methacrylate f

Thienopyrimidines as β3-adrenoceptor agonists: Hit-to-lead optimization

Resulting from a vHTS based on a pharmacophore alignment on known β3-adrenoceptor ligands, an aryloxypropanolamine scaffold comprising a thienopyrimidine moiety was further optimized as a human β3-AR agonist, yielding a lead compound with an excellent cellular activity of EC50 = 20 pM, selectivity over hβ1- and hβ2-adrenoceptors and a promising safety profile.

Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments

This invention relates to novel aryloxypropanolamines. The invention also relates to the pharmaceutically acceptable salts and solvates containing said compounds, methods for the preparation thereof and to respective synthesis intermediates. Said compound